Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (11109)	10/19/2017 10:43:19 AM
From: tuck	Read Replies (2) \| Respond to of 12215

Corbus had fireworked early on what looks like pretty bullet proof data in dermatomyositis: Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis Although the numbers aren't given for baseline characteristics and side effects, the PR claims they are balanced and copacetic, respectively (and no dropouts bolsters the latter case). I doubt bears will be able to construct a case until the ACR late breaker becomes available, and maybe not even then. The only caveat I can come up with is the n is a bit small, and stat sig was just barely hit. I had somewhat bought the bear case on the shakiness of the data, enough to exit with profit and just watch, but now . . . there apparently isn't much competition in this indication. but note the dosing difference. Trial started QD, didn't see a big effect, then went BID and bingo, p=0.02, which is better than barely. Suggests they use that dose from the beginning, since no safety signal. Cheers, Tuck